Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2025

Original Article

SGLT2 inhibitors and liver-related outcomes in diabetes

Sodium-Glucose Cotransporter2 inhibitors and associated Liver-Related outcomes in diabetes patients.

Diabetes research and clinical practice

Citation & Authors

Diabetes Res Clin Pract. 2025;223:112174.

Fu-Shun Yen; James Cheng-Chung Wei; Chen Wang; Ming-Chih Hou; Teng-Shun Yu; Yuhan Huang; Chii-Min Hwu; Chih-Cheng Hsu

ABSTRACT · RESEARCH SUMMARY

Research summary

This Taiwanese National Health Insurance study evaluated liver outcomes in patients with diabetes after excluding viral hepatitis and alcohol-related disease. Over a mean follow-up of approximately 2.7 years, SGLT2 inhibitor use was associated with lower risks of cirrhosis (aHR 0.78; 95% CI 0.70–0.87), decompensation, hepatic failure, and all-cause mortality. Some favorable associations were also observed in comparisons with other glucose-lowering drugs, although treatment-selection differences must be considered.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗